Because patients with absent/low intratumoral infiltration of CD8+ T-cell have a statistically significant shorter DFS and OS, they may deserve further treatments to reduce the recurrence rate and ultimately progression of melanoma. The gene discussed is CD8A; the disease is melanoma.